Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank
LOS ANGELES, March 10, 2023 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today confirms that neither ImmixBio, nor any of its subsidiaries, have any exposure to Silicon Valley Bank (“SVB”) or Silvergate Bank. About Immix Biopharma, Inc.Immix Biopharma, Inc. […]
Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank
LOS ANGELES, March 10, 2023 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today confirms that neither ImmixBio, nor any of its subsidiaries, have any exposure to Silicon Valley Bank (“SVB”) or Silvergate Bank. About Immix Biopharma, Inc.Immix Biopharma, Inc. […]